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Alpha fetoprotein (AFP) is synthesized by the
x human fetal liver and yolk sac [8, 9]. During
the 12th—14th intrauterine weeks the serum
concentration of AFP is at its highest, reaching
a few milligrams per ml [7]. However, the total
amount of AFP in the fetus increases until the
22nd week of gestation, remaining constant
until about the 32nd week, and thereafter de-
creasing [7]. In the newborn at term, the serum
AFP concentration is 50—ISO^g per ml [19].
AFP remains detectable by immunodiffusion or
related methods for about 5 weeks after birth
[24]. Greatly increased serum AFP levels cften
reappear in adults with primary hepatocellular
cancer [25] or teratocarcinomas [1]. Until
recently, the occurrence of AFP in maternal serum
had been contested [3].
We purified immunochemically human AFP
[14] and developed a radioimmunoassay (RIA)
for its determination [15]. It became evident thät
small amounts (2—16 ng per ml) of AFP are
present in normal human serum [15, 16].
This finding has now been confirmed by other
groups [6, 13]. AFP levels in maternal serum
increase during pregnancy and the highest
AFP concentrations occur during the third
trimester. The half life of maternal serum AFP
after delivery is about 5 days [19]. In amniotic
fluid, the AFP concentrations decrease from
the 15th week of gestation, and at term the
concentrations are similar to those in maternal
serum [19, 21].
Recently, we found that the maternal serum
AFP concentration often increases in asso-
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ciation with fetal death [20], and that this
increase may occur even before the fetal death
[23]. In the present paper we describe results on
the AFP concentrations in normal and patho-
logical pregnancies, and evaluate the clinical
significance of the serum AFP levels in the
antenatal diagnosis of high risk pregnancies.
1. Materials
1.1 Serum samples from pregnant women
Sera from 204 pregnant women between the 8th and the
42nd week of gestation were studied for the normal ränge.
The following types of high risk pregnancies were in-
vestigated: 67 sera from 20 diabetic women, 116 specimens
from 74 pregnant women with toxemia or hypertension,
and 48 samples from 27 pregnant women with a liver
disorder. Intrauterine fetal death occurred in 22 patients.
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1.2 Amniotic fluid samples
Amniotic fluid specimens were collected from 55 normal
pregnancies. Fifty-three specimens were collected through
an amnioscope by rupturing the fetal membranes, and 2
samples by puncture through the abdominal wall. Eight
specimens from 4 high risk pregnancies with severe
fetoplacental dysfunction (3 diabetic patients and l with
hydramnion and fetal meningomyelocele) were obtained
through abdominal taps. Samples contaminated with red
blood were discarded.
1.3 Homologous antibodies to AFP
Sera from 10 normal and 10 toxemic pregnancies were
collected A—19 weeks after delivery for the study of AFP
antibodies. Serum samples from a further case where
twins died in utero were also studied 3—7 weeks after the
delivery (Fig.6).
2. Methods
2.1 Radioimmunoassay of AFP
AFP was measured by the double antibody radioimmuno-
assay, äs described previously [15]. Serum and amniotic
fluid samples were usually assayed at dilutions of 1:25 or
higher.
2.2 AFP in the early human conceptus
After curettage of a 4-week-old pregnancy, the uterine
contents were homogenized in an equal volume (2.5 ml)
of saline by teasing them several times through a No. 16
injection needle. After centrifugation, the supernatant and
the corresponding maternal serum were examined for
AFP in RIA.
2.3 Search for homologous AFP antibodies
The test sera were incubated with 125I-AFP, after which
the precipitation was performed by adding anti-human
gamma globulin serum prepared in rabbits. The presence
of human antibodies to AFP in the test sera would in-
crease the radioactivity of the precipitate under the test
conditions.
2.4 Assessment of the predictive efficacy of the AFP
test in fetoplacental dysfunction
The normal ränge was calculated by determining the
95% tolerance limits for the AFP concentrations in
204 normal pregnancies [10]. AFP concentrations above
or below this ränge were considered abnormal. Severe
fetoplacental dysfunction was assumed when two or more
of the following signs were present [23]: abnormal fetal
heart action (late deceleration or Variation greater than
110—170 beats per min), fetal acidosis below pH 7.25,
meconium in amniotic fluid, retarded intrauterine growth,
and intrauterine fetal death. The occurrence of severe
fetoplacental dysfunction in the group with normal AFP
levels was compared with the group with abnormal AFP
concentrations. Clinical decisions were not governed by
the AFP concentrations.
3. Results
3.1 AFP in the early human conceptus
The supernatant of the uterine contents obtained
by curettage contained 325 ng o£ AFP in a volume
of 2.5 ml, while the corresponding maternal serum
AFP concentration was 24 ng per ml.
3.2 Ninety-five per cent tolerance limits for
the AFP concentrations
The maternal serum AFP concentration in-
creased from the 8th week of pregnancy. Between
8 and 12 weeks, about one half of the values
were above the upper non-pregnant level (16 ng
per ml). The 95% tolerance limits for the AFP
concentrations äs a function of duration of
pregnancy are given in Fig. 1. The highest AFP
concentrations occurred between 28 and 36
weeks of gestation, where the upper AFP level
was about 500 ng per ml.
3.3 Maternal serum AFP concentrations in
diabetic pregnancies
Of the 67 serum samples from 20 diabetic patients,
the highest individual AFP concentrations ex-
ceeded the normal ränge in 4 cases (20%) (Fig. 2).
Fetal distress was present in all of these patients,
while distress was found in only 4 of the 16
women (25%) whose AFP concentrations were
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Fig. 1. The 97.5, 50 and 2.5 percentiles (= nonparametric
estimation [10]) of the normal AFP concentratiors äs
functions of pregnancy weeks.
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Fig. 2. The highest individual serum AFP concentrations
in 20 pregnant women with diabetes mellitus. The larger
dots represent severe fetoplacental dysfunction. The
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Fig. 3. The highest individual serum AFP concentrations
in 74 pregnant women with toxemia or hypertension. The
larger dots indicate severe fetoplacental dysfunction. The
broken line connecting smaller and larger dots indicates
cases where the fetus died in utero: the smaller dots in
these cases indicate the AFP concentrations measured at
the time when the fetus was alive. The normal r nge is
shown by the shaded area.
3.4 Maternal serum AFP concentrations in
patients with toxemia or hypertension
Abnormal serum AFP concentrations were
present in 14 o£ the 74 patients (19%) with
toxemia or hypertension (Fig. 3). Severe feto-
placental dysfunction was found in 7 patients
with abnormal AFP concentrations (50%) and in
4 of the 56 women (7%) with normal AFP
levels.
3.5 Maternal serum AFP concentrations in
pregnant women with a liver disorder
Four o£ the 27 patients (15%) with a liver dis-
order had abnormal serum AFP concentrations
(Fig. 4). Severe fetoplacental dysfunction was
associated with 2 of these (50%), and with 3 of
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Fig. 4. The highest individual serum AFP concentrations
in 27 pregnant women with a liver disorder. The larger
dots indicate severe fetoplacental dysfunction. The broken
line connecting smaller and larger dots indicates cases
where the fetus died in utero: the smaller dots in these
cases indicate the AFP concentrations measured at the
time when the fetus was alive. The normal r nge is shown
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Fig. 5. The highest observed individual serum AFP
concentrations in 22 women whose fetus died in utero.
The broken line indicates cases where the AFP concen-
trations were measured while the fetus was still alive: the
smaller dots in these cases indicate the AFP concentrations
of living fetuses.
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Tab. I. Maternal serum AFP concentrations and feto-
placental function
1 2 3 4 5 6 7
Weeks öf te r O e l i v e r y
Fig. 6. The AFP concentrations in maternal serum in a
case where twins died in utero during the 26th weck of
gestation. The calculated half life of AFP was 4.2 days.
3.6 Intrauterine fetal death
The serum AFP concentrations in the 22 women
whose fetus died in utero were abnormal in
15 patients (68%): the concentrations increased
in 14 women and were abnormally low in one
patient at the time of fetal death (Fig. 5). In a
case where twins died in utero during the 26th
week of gestation, the AFP concentrations
remained above the upper normal pregnancy
level for 10 days after delivery (Fig. 6), and the
estimated half life of AFP was 4.2 days in this
case. Out of the 4 cases where the AFP concen-
trations were measured before the intrauterine
fetal death occurred, increased levels were
found in 3 (Fig. 5).
3.7 Assessment of severe fetoplacental dys-
function by the AFP test
The compiled data from Figs. 2 to 5 indicate that
abnormal serum AFP concentrations were
associated with severe fetoplacental dys-
function in 59% of the cases, while normal
AFP levels coincided with fetal distress in only
11% (Tab. I). The difference is highly significant
(p < 0.001).
AFP concentration Fetoplacental function
Normal Severe dysfunction
Normal (N = 99)





3.8 AFP concentrations in normal amniotic
fluid
The AFP concentrations in normal amniotic
fluid decreased during gestation. The mean
values were 316 ng per ml at 35—36 weeks,
164 ng per ml at 37—38 weeks, 115 ng per ml at
39—40 weeks, and 87 ng per ml at 41—42 weeks
(Fig. 7).
3.9 AFP concentrations in amniotic fluid of
high risk pregnancies
The AFP concentration in the amniotic fluid of
3 diabetic women increased äs the pregnancy
advanced during the third trimester. A significant
increase in the corresponding maternal serum
AFP concentration occurred in one of these
No.of coses
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Fig. 7. The mean AFP concentrations and the ränge in
55 amniotic fluid specimens from normal pregnancies.
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Fig. 8. The AFP concentrations in maternal serum (s) and
amniotic fluid (a) in 4 patients with severe fetoplacental
dysfunction. Patients a, b and c are diabetic, and d re-
presents a case where maternal hydramnion was associated
with fetal meningomyelocele. Fetus d died in utero.
patients, all of whom were diagnosed äs having
severe fetoplacental dysfunction (Fig. 8 a—c).
Polyhydramnion was present in one patient with
an amniotic fluid AFP concentration of 400 ng
per ml at the 26th week of gestation. The fetus
was alive at that time, but died in utero a week
later. The AFP concentration at this time was
48000 ng per ml (Fig. 8d). The fetus appeared
to have meningomyelocele.
3.10 Homologous AFP antibodies
Serum samples from 10 normal and 11 pathologic
pregnancies did not bind labeled 125I-AFP at
any time (3—19 weeks) after delivery. The
result shows that there were no homologous
circulating antibodies to AFP that could be
demonstrated with the radioimmunoassay em-
ployed.
4 Discussion . f
4.1 The source of AFP
Alpha fetoprotein was present at a higher con-
centration in the products of conception than in
the maternal serum, which suggests that AFP is
being synthesized at an early stage (4 weeks)
of pregnancy by the human conceptus.
4.2 Increased maternal AFP levels
Abnormally high circulating maternal AFP
concentrations were most frequently seen in
women whose fetuses died in utero. However,
moderate elevations above the normal pregnancy
ränge were also found in women with severe
fetoplacental dysfunction. We assume that the
increased maternal AFP originates from the
fetus in these conditions, although increased
maternal AFP concentrations could be anticipated
under circumstances in which the maternal liver
is affected. This has been observed in some
non-neoplastic liver diseases [2, 17]. The in-
creased fetal AFP in the maternal circulation may
result from an increased fetal AFP concentration,
increased transplacental passage of fetal blood,
or transmission of fetal elements from the
amniotic fluid to the mother. While all these
mechanisms may be operating, there is preli-
minary evidence indicating that distressed new-
born infants have higher AFP concentrations
than normal infants of similar gestational ages
[12].
4.3 Low maternal AFP levels
The significance of low maternal AFP levels is
not established. In one patient whose fetus died
in utero during the 38th week of gestation, the
maternal serum AFP concentration was 20 ng
per ml, and rose to 28 ng per ml after delivery.
In the case of a fetal meningomyeloce^ (Fig. 8d),
the maternal serum AFP level was low (30 ng
per ml) even at a time when the amniotic fluid
AFP level had increased to 48000 ng per ml. In
anöther case of severe pre-eclampsia with a
distressed fetus, the maternal serum AFP con-
centration was only 26 ng per ml. It is possible
that certain types of diseases lead to increased
maternal serum AFP concentrations, while others
do not.
J. Perinat. Med. l (1973)
Seppälä et al., Alpha fetoprotein: Physiology and pathology during pregnancy and application to antenatal diagnosis 109
4.4 Fetal distress and normal maternal AFP
levels
While abnormal maternal serum AFP concen-
trations were associated with severe fetoplacental
dysfunction in 59% of the cases, fetal distress
occurred in 11% of the women with normal AFP
levels. There were 4 women whose fetal distress
was correctly indicated by the maternal serum
AFP concentration, while the estriol excretion
was normal. Our results suggest that the serum
AFP level can increase the cumulative efficacy of
the biochemical methods used f or the monitoring
of high risk pregnancies. Even if used alone,
high circulating maternal AFP levels are in-
formative from the clinical point of view, since
obstetrical decisions in high risk pregnancies
rest largely upon the evaluation of risks associated
with Intervention versus those of waiting,
provided that the fetus is considered viable.
4.5 Amniotic fluid AFP levels in normal
pregnancies
The AFP concentration in amniotic fluid can
indicate the gestational age of the fetus in
normal pregnancies. In a previous study we
showed that the decreasing AFP concentrations
in amniotic fluid were related to gestational age
rather than to the weight of the iüfant [21]. A
similar decrease occurs in fetal serum during
gestation [4]. AFP concentrations smaller than
185 ng per ml in amniotic fluid indicate that
pregnancy has advanced to at least the 37th week.
Our values f or amniotic fluid AFP concentrations
were smaller than those reported by BROCK and
SUTCLIFFE [5], who found AFP concentrations of
äs high äs 6000 ng per ml in amniotic fluid
samples from the 39th week of gestation. This
disagreement can only partly be explained by the
different Standards used: a pure Standard gives
smaller concentrations than One less specific.
The BEHRINGWERKE Standard gives values for
AFP twice äs high äs ours [14].
4.6 Amniotic fluid AFP levels in pathological
pregnancies
The determination of gestational age by the
amniotic fluid AFP level seems to be obscured
by changes found in some pathological preg-
nancies. In the present series, we examined 4
cases where the AFP concentrations increased
at the time when fetal distress developed;
normally a decrease is observed. Increasing
amniotic fluid AFP concentrations may in
certain cases provide a more sensitive marker for
fetal distress than maternal serum AFP concen-
trations. This is indicated by the smaller increase,
or even a decrease in the serum AFP levels in
diabetic patients with fetoplacental dysfunction,
while the amniotic fluid AFP concentrations
increased (Fig. 8 a—c). We have recently found
that the AFP concentrations in amniotic fluid
increase in cases of severe maternal Rh-im-
munization or intrauterine fetal death where
no gross fetal malformations are present. It is
possible that the high AFP concentrations found
in the control samples of BROCK and SUTCLIFFE
[5] were related to Rh-immunization and, in the
light of the present results, it would be inter-
esting to know whether the remarkably high
AFP concentrations found in spina bifida and
anencephaly [5] were also related to fetal distress
or specifically to the underlying disease. Our
case of fetal meningomyelocele was associated
with a normal (400 ng per ml) amniotic fluid
AFP concentration during the 26th week, but
the AFP level increased to 48000 ng per ml
when the fetus died in utero. In addition to
fetal distress, leakage of AFP through the menin-
gomyelocele may also have contributed to the
marked increase in the amniotic fluid AFP con-
centration at the time of fetal death.
We found a moderately increased amniotic
fluid AFP level and a normal maternal serum
AFP concentration in another case where the
fetus died suddenly of a cord complication. It
seems that the increased circulating maternal
AFP concentrations reflect chronic rather
than acute fetoplacental dysfunction and
that the amniotic fluid AFP levels change
more rapidly.
4.7 The source of amniotic fluid AFP
Unlike other proteins in amniotic fluid [18, 22],
the direct source of the major portion of amniotic
fluid AFP seems to be the fetal urine [21], where
the AFP concentration is higher than in amniotic
fluid. This is true of early but not late pregnancy
J. Pcrinat. Mcd. l (1973)
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[21]. It would be interesting to know whether
the AFP concentrations in newborn urine are
higher in distressed than in normal infants.
4.8 Homologous AFP antibodies
The AFP concentration of 4200 ng per ml in
maternal serum in a case in which twins died in
utero (Fig. 6) indicates that more than 10 mg of
AFP had passed to the mother. However, no
human antibodies to homologous AFP were
detected in this case, during pregnancy [19], or
in the postpartum sera of several other cases
using the radioimmunoassay. Previous contact
with high serum AFP concentrations during the
embryonal period results in the recognition of
AFP äs a "seif", and the low AFP concentrations
in normal human serum are likely to maintain
tolerance to AFP. Recently, it has been shown
that rabbits produce antibodies to their homo-
logous AFP when immunized with human AFP
[11], which suggests that antibodies to AFP may
occur in humans. Radioimmunoassay is sensitive
for the detection of antibodies with a relatively
high affinity, and our results therefore do not
exclude the existence of low affinity antibodies in
the cases studied.
Summary
A. Alpha fetoprotein (AFP) was measured by a highly
sensitive radioimmunoassay in tissue homogenate of an
early human conceptus, maternal serum and amniotic
fluid in normal and high risk pregnancies. Human products
of conception contained more AFP than maternal serum
at the 4th week of gestation indicating that AFP is syn-
thesized by the human conceptus at this early stage
of development.
B. In maternal serum, the AFP concentrations in-
creased with advancing gestation: the highest levels
— about 500 ng per ml — were present during the mid-
third trimester; these values were based on the AFP
levels in 204 normal pregnancies (Fig. 1).
G. Circulating maternal AFP concentrations increased
in cases with severe fetoplacental dysfunction. In
67 serum samples from 20 diabetic pregnancies, the AFP
concentrations were above the normal ränge in 4 patients
(20%). Fetal distress was present in all these cases and in
4 of the 16 women (25%) whose AFP levels were within
the normal ränge (Fig. 2). In 74 pregnant women with
toxemia or hypertension, abnormal serum AFP concen-
trations were present in 14 (Fig. 3). Severe fetal distress
was present in 7 of these (50%) and in 4 out of the 60 women
(7%) whose serum AFP concentrations were within the
normal ränge. In patients with a liver disorder, 4 of 27 had
abnormal serum AFP concentrations (15%). Severe fetal
distress was present in 2 of these (50%) and in 3 of the 23
patients with normal AFP levels (13%) (Fig. 4). In 22
cases of intrauterine fetal death, abnormal maternal serum
AFP concentrations occurred in 15 patients (68%): the
AFP levels were increased in 14 women and abnormally
low in one (Fig. 5). There were 4 women whose serum
AFP concentrations were measured before intrauterine
fetal death occurred: the levels were found to be increased
in three. Fetal distress was correctly indicated by abnormal
maternal serum AFP concentrations in 4 cases where the
estriol excretion was normal. In all, abnormal AFP con-
centrations in maternal serum were associated with severe
fetoplacental dysfunction in 59% of the cases, while normal
levels coincided with fetal distress significantly less fre-
quently (11%) (p < 0.001, Tab. I).
D. We assume that the major part of the circulating
maternal AFP originales from the fetus, and that the
increase above the normal pregnancy ränge of maternal
serum AFP concentration can result from an increased
fetal serum AFP level, increased transplacental passage of
fetal blood, or transmission of fetal elements from the
amniotic fluid to the mother.
E. The maternal serum AFP concentrations remained
above the normal pregnancy ränge for 10 days, and above
the upper nonpregnant level for 30 days after delivery of
macerated twins* (Fig. 6)v The estimated half-life of
AFP was 4.2 days in this case.
F. In normal amniotic fluid, the AFP concentrations
decreased during gestation (Fig. °7). The mean AFP
levels (ng per ml) were: 316 at 35—36 weeks, 164 at
37—38 weeks, 115 at 39—40 weeks, and 87 at 41—42
weeks. Amniotic fluid AFP concentrations may indicate
the gestational age of the fetus in normal pregnancies.
G. In high risk pregnancies, increased AFP concen-
trations in amniotic fluid were associated with fetal
distress. In serial amniotic fluid samples from 3 diabetic
pregnancies, the AFP concentrations increased at the time
when fetal distress became clinically evident (Fig. 8 a—c).
In a case of fetal meningomyelocele, the AFP concentration
in amniotic fluid was normal in the first specimen, but
increased markedly at the time of intrauterine fetal death
(Fig. 8d). According t o these preliminary results it seems
that the AFP concentrations of both maternal serum
and amniotic fluid can be useful in the assessment of
fetal state in high risk pregnancies.
H. A radioimmunologic method was designed to
detect naturally occurring human antibodies to AFP.
No antibodies could be demonstrated 3—19 weeks after
normal or pathologic pregnancies. Previous contact
during the embryonal period with high serum AFP con-
J. Perinat. Med. l (1973)
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centrations would be expected to tesult in the recognition
o£ AFP äs a "seif" during the adult life, and the low AFP
concentrations in normal human serum are likely to
maintain tolerance to AFP so that even high circulating
maternal AFP concentrations are not sufficient to elicit an
immune response.
Key-words: Alpha fetoprotein (-antibodies, -physiology, -radioimmunoassay), amniotic fluid, fetus, pregnancy.
Zusammenfassung
Alpha-Fetoprotein: Physiologie und Pathologie wäh-
rend der Schwangerschaft und die Anwendung auf
die vorgeburtliche Zustandsdiagnose
A. Alpha-Fetoprotein (AFP) wurde mittels einer hoch-
empfindlichen Radioimmunmethode im Gewebshomo-
genat früher menschlicher Embryos und in Serum und
Fruchtwasser von Müttern mit normalen und Risiko-
schwangerschaften bestimmt. Menschliche Embryos ent-
hielten mehr AFP als mütterliches Serum in der vierten
Schwangerschaftswoche; dies zeigt an, daß AFP vom
menschlichen Embryo in diesem frühen Entwick-
lungsstadium synthetisiert wird. Im mütterlichen
Serum stiegen die AFP-Konzentrationen mit zu-
nehmender Schwangerschaftsdauer an: die höchsten
Werte — etwa 500 ng/ml — traten während der Mitte des
3. Trimenons auf. Dies wurde anahnd von 204 normalen
Schwangerschaften bestimmt (Abb. 1).
G. In Fällen mit schwerer feto-plazentarer Dysfunk-
tion waren die mütterlichen AFP-Konzentrationen
erhöht. In 67 Seren von 20 diabetischen Schwangeren
war die AFP-Konzentration bei 4 Frauen oberhalb des
Normbereiches (20%). In allen diesen Fällen bestand eine
fetale Störung, ebenso wie bei 4 von 16 Patientinnen
(25%) mit normalen AFP-Werten (Abb. 2). Von 74
Schwangeren mit Gestose oder Bluthochdruck waren ab-
norme AFP-Werte bei 14 vorhanden (Abb. 3). Bei 7 von
diesen (50%) bestand eine schwere fetale Störung; eine
solche lag in 4 der 60 Fälle (7%) mit normalen AFP-
Konzentrationen vor. 4 von 27 Patientinnen (15%) mit
einer Leberstörung hatten abnormale AFP-Werte. Von
diesen hatten 2 (50%) eine schwere fetale Störung, wäh-
rend dies bei 3 der 23 Patientinnen (13%) mit normalen
AFP-Werten der Fall war (Abb. 4). Von 22 Fällen mit
intrauterinem Fruchttod traten abnorme AFP-Werte bei
15 Patientinnen (68%) auf: die AFP-Werte waren erhöht
bei 14 und abnorm erniedrigt bei einer Patientin (Abb. 5).
Bei 4 Frauen wurden die AFP-Konzentrationen vor dem
Fruchttod bestimmt: die Werte waren bei drei von ihnen
erhöht. Eine fetale Störung wurde durch abnorme mütter-
liche AFP-Werte richtig angezeigt in 4 Fällen, in welchen
die Östriolausscheidung normal war. Im ganzen wurden
abnorme AFP-Konzentrationen in mütterlichen Seren in
59% aller Fälle von schwerer feto-plazentarer Dysfunktion
beobachtet, während normale Werte signifikant weniger
häufig (p < 0,001) bei einer fetalen Störung auftraten
, Tab. I)t
D. Wir nehmen an, daß der größte Teil des zirkulierenden
mütterlichen AFP vom Feten stammt und daß ein An-
stieg über den Bereich der normalen Schwangerschafts-
werte entweder von erhöhten fetalen AFP-Werten oder
von gesteigertem transplazentarem Übertritt von Fetal-
blut oder von der Übertragung fetaler Elemente vom
Fruchtwasser auf die Mutter stammen kann.
E. Mütterliche AFP-Werte blieben oberhalb des nor-
malen Schwangerschaftsbereiches für 10 Tage und ober-
halb der Normwerte..£ür Nichtschwangere für 30 Tage
nach der Geburt von mazerierten Zwillingen (Abb. 6).
Eie Halbwertszeit des AFP wurde in diesem Fall auf
4,2 Tage geschätzt.
F. Im normalen Fruchtwasser fielen die AFP-Werte im
Verlauf der Schwangerschaft ab. Die durchschnittlichen
AFP-Werte waren: 35—36 Wochen: 316 ng/ml; 37—38
Wochen: 164 ng/ml; 39—40 Wochen: 115 ng/ml; 41 bis
42 Wochen: 87 ng/ml. AFP-Fruchtwasserkonzentrationen
könnten das Gestationsalter von Feten bei normalen
Schwangerschaften anzeigen.
G. Bei Risikoschwangerschaften waren erhöhte AFP-
Fruchtwasserkonzentrationen mit fetalen Störungen
verbunden (Abb. 7). Fortlaufende Bestimmungen bei 3
diabetischen Schwangeren zeigten den Anstieg von AFP
zu dem Zeitpunkt an, als eine fetale Störung klinisch fest-
gestellt wurde (Abb. 8a—c). Bei einem Fet mit einer
Myelomeningocele war die AFP-Konzentration im Frucht-
wasser zunächst normal, stieg jedoch zur Zeit des in-
trauterinen Fruchttodes beträchtlich an (Abb. 8d). Diese
vorläufigen Ergebnisse scheinen auf den Wert der AFP-
Bestimmung im mütterlichen Serum und im Frucht-
wasser für die Zustandsdiagnose von Feten bei Risiko-
schwangerschaften hinzuweisen.
H. Es wurde eine Radioimmunmethode zur Bestim-
mung natürlich vorkommender menschlicher Anti-
körper gegen AFP entwickelt. Es konnten keine Anti-
körper 3 bis 19 Wochen nach einer normalen oder patho-
logischen Schwangerschaft entdeckt werden. Ein voraus-
gegangener Kontakt mit hohen AFP-Konzentrationen
während der Embryonalperiode könnte zur Erkennung
des AFP als „seif" beim Erwachsenen führen. Die nie-
drigen AFP-Werte im normalen menschlichen Serum
bewirken wahrscheinlich eine Toleranz gegen AFP, so
daß selbst hohe mütterliche AFP-Werte nicht zur Aus-
lösung einer Immunreaktion führen.
Schlüsselwörter: Alpha-Fetoprotein (-Antikörper, -Physiologie, -Radioimmunbestimmung), Fetus, Fruchtwasser,
(Risiko-)Schwangerschaft.
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Resume
Alpha foeto-proteine: physiologie et pathologie lots
de la grossesse, et application aux diagnostics -
nataux
A. L'Alpha foeto-proteine (A. F. P) a ete dosee par une
methode radio-immunologique, methode particulierement
sensible, dans un homogeinat de tissus provenant d'un
embryon humain tres jeune, dans le serum maternel et le
liquide ammiotique de grossesses normales et de gros-
sesses a haut risque.
Le foetus humain contenait plus d'A. F. P. que le serum
maternel a la 4eme semaine de- la grossesse, indiquant
que . F. P. est synthetisee par le foetus ä ce stade
tres precoce du developpement.
B. Dans le serum maternel, le taux d'A. F. P. aug-
mente avec le terme: les taux les plus hauts, de l'ordre de
500 n. g. par millilitre, ont ete trouves au milieu du troi-
sieme trimestre (etude portant sur le taux d'A. F. P. de
204 grossesses normales; fig. 1).
X3. Le taux circulant d'A. F. P. maternel est augmente
dans les cas qui comportent un dysfonctionnement
foeto-placentaire severe. Dans une serie de 67 echantillons
de serum provenant de 20 femmes enceintes diabetiques,
le taux d'A. F. P. etait superieur a la normale chez 4 pa-
tientes (20%). La souffrance foetale existait dans tous ces
cas mais aussi chez 4 des 16 femmes (25%) dont le taux
d'A. F. P. etait sensiblement normal (fig. 2).
Chez 74 femmes enceintes, presentant une toxemie gra-
vidique ou. une hypertension, des concentrations anor-
males d'A. F. P. existaient dans 14 cas (fig. 3). Une souf-
france foetale severe existait 7 fois sur ces 14 cas (50%)
mais aussi chez 4 des 60 femmes (7%) dont le taux d'A. F. P.
etait sensiblement normal.
Parmi les 27 patientes presentant une affection hepatique,
4 avaient un taux anormal d'A. F. P. (15%), une souf-
france foetale severe existait chez deux d'entre elles (50%)
et chez 3 des 23 patientes ayant des taux normaux d'A. F. P.
(13%) (fig. 4).
Dans 22 cas de mort foetale in utero, des taux maternels
anormaux d'A. F. P. furent trouves chez 15 patientes
(68%): eleves dans 14 cas, anormalement bas dans un
cas (fig. 5). Dans 4 autres cas, on a pu mesurer le taux
maternel d'A. F. P. avant la mort foetale: il etait eleve dans
trois cas.
La souffrance foetale a ete correctement detectee par un
chiffre anormal d'A. F. P. dans 4 cas oü l'oestriol urinaire
etait normal.
En bref un taux anormal d'A. F. P. dans le serum maternel
etait associe a un dysfonctionnement foeto-placentaire
severe dans 59% des cas, tandis que des taux normaux
comcidaient avec une souffrance foetale nette avec une
frequence moindre (11%) (p < 0.001,tab. I).
D. Nous pensons que la plus grande partie de FA. F. P.
circulante chez la mere provient du foetus, et que
l'augmentation du taux serique maternel d' A. F. P. au-
dessus du taux gravidique normal peut provenir soit
d'un taux serique foetal augmente, soit d'un passage
sanguin foeto-maternel augmente, ou bien d'un passage
d'elements foetaux du liquide amniotique vers la mere.
E. A la suite de l'accouchement de deux jumeaux maceres,
le taux serique maternel d'A. F. P. s'est maintenu au-
dessus du taux gravidique normal pendant 10 jours, et
au-dessus du taux maximum que peut rencontrer en
dehors de la grossesse pendant 30 jours (fig. 6). La demi-
vie de l'A. F. P. estimee dans ce cas est de 4,2 jours.
F. Dans le liquide ammiotique normal, la concen-
tration d'A. F. P. decroit pendant la gestation. Les
taux moyens d'A. F. P. (nanogramme par millilitre)
etaient de: 316 a 35—36 semaines, 164 ä 37—38 semaines,
115 a 39—40 semaines, 87 a 41—42 semaines.
La concentration amniotique d'A. F. P. peut etre suscep-
tible d'indiquer l'äge gestationnel d'un foetus lors d'une
grossesse normale.
G. Dans les grossesses a haut risque des taux d'A. F. P.
augmentes dans le liquide amniotique etaient as-
socies a une souffrance foetale (fig. 7). Dans des series
d'echaritillons de liquide amniotique provenant de 3
femmes enceintes diabetiques, la concentration amniotique
d'A. F. P. a augmente au moment oü la souffrance foe-
tale devenait cliniquement evidente (fig. 8 a—c).
Dans un cas de myelomeningocele, la concentration
amniotique d'A. F. P. etait normale dans le premier
echantillon, mais a augmente tres notablement au moment
de la mort foetale in utero (fig. 8d).
Selon ces premiers resultatsv il semble que le taux d'A. F. P.
aussi bien dans le serum maternel que dans le liquide
amniotique puisse etre un element utile d'appreciation
de l'etat foetal dans les grossesses a haut risque.
H. Une methode radio-immunologique etait apte a
detecter des anticorps naturels anti A. F. P. II n'en a
pas ete trouve 3 ä 19 semaines apres des grossesses nor-
males ou pathologiques.
Un contact prealable pendant la periode embryonnaire
avec de hautes concentrations seriques d'A. F. P. est
susceptible d'expliquer la reconnaissance ulterieure de
A. F. P. comme «non etrangere» a Tage ädulte; de plus,
l'existence d'un tres faible taux serique d'A. F. P. chez
l'adulte normal est susceptible de maintenir une tolerance
vis a vis de . F. P. de teile maniere que meme les taux
eleves chez la femme enceinte ne sont plus susceptibles
d'induire une reponse immunitaire.
Mots-cles: Alpha foeto proteine (-anticorps, -dosage radioimmunologique, -physiologie), grossesse (-ä haut risque),
foetus, liquide amniotique, souffrance foetale.
Acknowledgements
We thank Prof. P. VARA, M. D., and Prof. S. TIMONEN, M. D., for the clinical material, Miss S. SOIKKELI, Miss H.
KALLIO, Miss S. RISTIMÄKI and Miss L. SALMINEN for technical assistance, and Mr. T. PARTANEN, M. Sc., for statistical
advice. This study was supported by grants from the Finnish Medical Research Council and the Sigrid Juselius Foundation.
J. Perinat. Mcd. l (1973)
Seppälä et al., Alpha fetoprotein: Physiology and pathology during pregnancy and application to antenatal diagnosis 113
Bibliogtaphy
[1] ABELEV, G. L, I. V. ASSERCRITOVA, N. A. KRAEVSKY,
S. D. PEROVA, N. L PEREVODCHIKOVA: Embryonal
serum -globulin in cancer patients: diagnostic value.
. Int. J. Cancer 2 (1967) 551
[2] ABELEV, G. I., V. S. TSVETKOV, T. L BIRYULINA,
D. A. ELGORT, A. M. OLOVNIKOV, A. L GUSEV,
A. K. YAZOVA, S. D. PEROVA, L V. RUBTSOV, S. V.
SHABORINA, B. A. KANTOROVICH, V. M. TÜR, A. I.
KHAZANOV, D. M. LEVINA: Assessment of the use of
highly sensitive methods of determining alpha-feto-
protein for the diagnosis of hepatocellular cancer and
teratoblastoma. Biull. eksp. Biol. Med. 4 (1971) 75
[3] ALPERT, E., J. ZUCKERMAN: Absence of arfetoprotein
antigen or antibody in maternal sera. Lancet (1970)
II, 465
[4] BERGSTRAND, C. G., B. W. KARLSSON, T. LINDBERG,
H. EKELUND: -foetoprotein, albumin and total
protein in serum from preterm and term infants and
small for gestational age infarts. Acta Paediat. Scand.
61 (1972) 128
[5] BROCK, D. J. H., R. G. SUTCLIFFE: Alpha-fetoprotein
in the antenatal diagnosis of anencephaly and spina
bifida. Lancet (1972) II, 197
[6] ELGORT, D. A., G. L ABELEV, G. T. O'CONOR:
Dependence of the specificity of the Serologie test for
primary liver cancer in different areas of the world on
sensitivity of the method used for detecting alpha-
fetoprotein. Int. J. Cancer 10 (1972) 331
[7] GITLIN, D., M. BOESMAN: Serum a-fetoprotein,
albumin and y-globulin in the human conceptus. J.
Clin. Invest. 45 (1966) 1826
[8] GITLIN, D., M. BOESMAN: Sites of serum a-feto-
protein synthesis in the human and in the rat. J. Clin.
Invest. 46 (1967) 1010
[9] GITLIN, D., A. PERRICELLI: Synthesis of serum
albumin, prealbumin, -foetoprotein, arantitrypsin and
transferrin by the human yolk sac. Nature (Lond.)
228 (1970) 995
[10] HERRERA, L.: The precision of percentiles in estab-
lishing normal limits in medicine. J. Lab. Clin. Med.
52 (1958) 34
[11] NISHI, S., H. WATABE, H. HIRAI: Production of
antibody to homologous -fetoprotein in rabbits,
rats and horses by immunization with human a-feto-
protein. J. Immunol. 109 (1972) 957
[12] N0RGAARD-PEDERSEN, B.: Personal communication
1972
[13] PURVES, L. R., M. PURVES: Serum alpha-feto-protein.
VI. The radio-immunoassay evidence for the presence
of AFP in the serum of normal people and during
pregnancy. South Afr. Med. J. 46 (1972) 1290
[14] RUOSLAHTI, E., M. SEPPÄLÄ: Studies of carcino-
fetal proteins: Physical and chemical properties of
human -fetoprotein. Int. J. Cancer 7 (1971) 218
[15] RUOSLAHTI, E., M. SEPPÄLÄ: Studies of carcino-fetal
proteins. III. Development of a radioimmunoassay for
-fetoprotein. Demonstration of -fetoprotein in
serum of healthy human adults. Int. J. Cancer 8
(1971) 374
[16] RUOSLAHTI, E., M. SEPPÄLÄ: -foetoprotein in normal
human serum. Nature (Lond.) 235 (1972) 161
[17] RUOSLAHTI, E., M. SEPPÄLÄ: Normal and increased
alpha-fetoprotein in neoplastic and non-neoplastic
liver disease. Lancet (1972) II, 278
[18] RUOSLAHTI, E., T. TALLBERG, M. SEPPÄLÄ: Origin of
proteins in amniotic fluid. Nature (Lond.) 212 (1966)
841
[19] SEPPÄLÄ, M., E. RUOSLAHTI: Radioimmunoassay of
maternal serum alpha fetoprotein during pregnancy
and delivery. Amer. J. Obstet. Gynec. 112 (1972) 208
[20] SEPPÄLÄ, M., E. RUOSLAHTI: -fetoprotein in normal
and pregancy sera. Lancet (1972) I, 375
[21] SEPPÄLÄ, M., E. RUOSLAHTI: Alpha fetoprotein in
amniotic fluid: An index of gestational age. Amer. J.
Obstet. Gynec. 114 (1972) 595
[22] SEPPÄLÄ, M., E. RUOSLAHTI: Proteins and non-
protein nitrogen compounds in amniotic fluid and
their clinical significance. Scand. J. clin. Lab. Invest.
29 (1972) suppl. 126
[23] SEPPÄLÄ, M., E. RUOSLAHTI: Alpha fetoprotein in
maternal serum: a new marker for detection of fetal
distress and intrauterine death. Amer. J. Obstet.
Gynec. 115 (1973) 48
[24] SEPPÄLÄ, M., T. TALLBERG, C. EHNHOLM: Studies on
embryo-specific proteins. Physiological characteristics
of embryo-specific alpha-globulin. Ann. Med. exp.
Fenn. 45 (1967) 16
[25] TATARINOV, Y. S.: Content of embryo-specific
alpha-globulin in the blood serum of human foetus,
newborn and adult man in primary cancer of liver.
Vop. med. Khim. 11 (1965) 20
M. Seppälä, M. D.
University Central Hospital
Dept. II of Obstetrics & Gynecology
SF-00290 Helsinki 29
Finland
J. Perinat. Med. l (1973)
